Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hodges, Melissa
NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention	Terminated	2/3	1753	US	BHV-3500 (zavegepant), Placebo	Pfizer	Migraine	03/24	03/24
NCT05837338: Treatment of Post-Punch Biopsy Bleeding in Anticoagulated Patients Using Self-Administered BXP154	Completed	2	24	US	BXP154, Placebo	Bio 54, LLC	Wound Bleeding	07/23	07/23
NCT06205615: Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B	Completed	2	24	US	BXP154B, Placebo, Punch Biopsy	Bio 54, LLC	Wound Bleeding	03/24	03/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hodges, Melissa
NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention	Terminated	2/3	1753	US	BHV-3500 (zavegepant), Placebo	Pfizer	Migraine	03/24	03/24
NCT05837338: Treatment of Post-Punch Biopsy Bleeding in Anticoagulated Patients Using Self-Administered BXP154	Completed	2	24	US	BXP154, Placebo	Bio 54, LLC	Wound Bleeding	07/23	07/23
NCT06205615: Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B	Completed	2	24	US	BXP154B, Placebo, Punch Biopsy	Bio 54, LLC	Wound Bleeding	03/24	03/24